Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis

References

• Tapper EB, Catana AM, Sethi N, et al. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. Cancer. 2016;122(6):852–858. doi: 10.1002/cncr.29855.
   PubMed Web of Science ®Google Scholar
• Brar G, Kesselman A, Malhotra A, et al. Redefining intermediate-stage HCC treatment in the era of immune therapies. J Clin Oncol Oncol Pract. 2022;18(1):35–41. doi: 10.1200/op.21.00227.
   Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation barcelona clinic liver cancer (BCLC) staging system. The 2022 update. J Hepatol. 2022;76(3):681–693. doi: 10.1016/j.jhep.2021.11.018.
   PubMed Web of Science ®Google Scholar
• Nazzal M, Gadani S, Said A, et al. Liver targeted therapies for hepatocellular carcinoma prior to transplant: contemporary management strategies. Glob Surg. 2018;4(1): doi: 10.15761/gos.1000171.
   PubMedGoogle Scholar
• Food and Drink Administration. Recently approved devices: therasphere – P200029. 2021. Available from: https://www.fda.gov/medical-devices/recently-approved-devices/theraspheretm-p200029.
   Google Scholar
• Kim MA, Jang H, Choi NR, et al. Yttrium-90 radioembolization is associated with better clinical outcomes in patients with hepatocellular carcinoma compared with conventional chemoembolization: a propensity score-matched study. J Hepatocell Carcinoma. 2021;8:1565–1577. doi: 10.2147/jhc.S335879.
   PubMed Web of Science ®Google Scholar
• Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155–1163 e2. doi: 10.1053/j.gastro.2016.08.029.
   PubMed Web of Science ®Google Scholar
• Dhondt E, Lambert B, Hermie L, et al. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303(3):699–710. doi: 10.1148/radiol.211806.
   PubMed Web of Science ®Google Scholar
• Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342–2352. doi: 10.1002/hep.31819.
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9(8):1920–1928. doi: 10.1111/j.1600-6143.2009.02695.x.
   PubMed Web of Science ®Google Scholar
• Gabr A, Kulik L, Mouli S, et al. Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-Patient cohort. Hepatology. 2021;73(3):998–1010. doi: 10.1002/hep.31318.
   PubMed Web of Science ®Google Scholar
• Manas D, Bell JK, Mealing S, et al. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization. Eur J Surg Oncol. 2021;47(2):401–408. doi: 10.1016/j.ejso.2020.08.027.
   PubMed Web of Science ®Google Scholar
• Ham C. Money can’t buy you satisfaction. BMJ. 2005;330(7491):597–599. doi: 10.1136/bmj.330.7491.597.
   PubMedGoogle Scholar
• Rostambeigi N, Dekarske AS, Austin EE, et al. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2014;25(7):1075–1084. doi: 10.1016/j.jvir.2014.04.014.
   PubMed Web of Science ®Google Scholar
• National Liver Review Board (NLRB). Guidance to liver transplant programs and the national liver review board for: adult MELD exceptions for hepatocellular carcinoma (HCC). 2022.
   Google Scholar
• Teyateeti A, Mahvash A, Long JP, et al. Survival outcomes for yttrium-90 transarterial radioembolization with and without sorafenib for unresectable hepatocellular carcinoma patients. J Hepatocell Carcinoma. 2020;7:117–131. doi: 10.2147/jhc.S248314.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103. doi: 10.1001/jama.2016.12195.
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation segmentectomy: Potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287(3):1050–1058. doi: 10.1148/radiol.2018171768.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48(6):571–577. doi: 10.1016/j.dld.2016.02.005.
   PubMedGoogle Scholar
• Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–264. doi: 10.1038/bjc.2014.199.
   PubMed Web of Science ®Google Scholar
• Seshadri RM, Besur S, Niemeyer DJ, et al. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB. 2014;16(12):1102–1109. doi: 10.1111/hpb.12300.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma [ID1089]. London: National Institute for Health and Care Excellence; 2018.
   Google Scholar
• Lim KC, Wang VW, Siddiqui FJ, et al. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the milan criteria. Hepatology. 2015;61(1):227–237. doi: 10.1002/hep.27135.
   PubMed Web of Science ®Google Scholar
• York Health Economics Consortium. Utility. 2016. Available from: https://yhec.co.uk/glossary/utility/.
   Google Scholar
• Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803–816. doi: 10.1007/s11136-020-02650-y.
   PubMed Web of Science ®Google Scholar
• UNOS. OPTN Metrics (Liver): UNOS. 2021 [cited 2021 Oct]. Available from: https://insights.unos.org/OPTN-metrics/.
   Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi: 10.1056/NEJMoa0708857.
   PubMed Web of Science ®Google Scholar
• Bellavance EC, Lumpkins KM, Mentha G, et al. Surgical management of early-stage hepatocellular carcinoma: resection or transplantation? J Gastrointest Surg. 2008;12(10):1699–1708. doi: 10.1007/s11605-008-0652-2.
   PubMed Web of Science ®Google Scholar
• Bentley TS, Ortner N. 2020 U.S. organ and tissue transplants: cost estimates, discussion, and emerging issues. Milliman Research Report; Seattle, WA; 2020.
   Google Scholar
• Arias E. United States Life. Tables, 2017. National vital statistics reports: from the centers for disease control and prevention, national center for health statistics. Natl Vital Stat Sys. 2019;68(7):1–66.
   Google Scholar
• Centers for Medicare & Medicaid Services. Healthcare cost report information system. 2020 [cited 2021 June]. Available from: https://www.cms.gov/.
   Google Scholar
• IBM. IBM Micromedex RED BOOK. Colorado: IBM. 2021 [cited 2021 March]. Available from: https://www.ibm.com/uk-en/products/micromedex-red-book.
   Google Scholar
• U.S. Bureau of Labor Statistics. CPI inflation calculator. 2021 [cited 2021 June]. Available from: https://www.bls.gov/data/inflation_calculator.htm.
   Google Scholar
• Sermo. 2022 [cited 2022 Jan 18]. Available from: https://www.sermo.com/.
   Google Scholar
• Walton M, Wade R, Claxton L, et al. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Health Technol Assess. 2020;24(48):1–264. doi: 10.3310/hta24480.
   PubMed Web of Science ®Google Scholar
• York Health Economics Consortium. Quality-adjusted life year. 2016. Available from: https://yhec.co.uk/glossary/quality-adjusted-life-year-qaly/.
   Google Scholar
• York Health Economics Consortium. Incremental cost-effectiveness ratio. 2016. Available from: https://yhec.co.uk/glossary/incremental-cost-effectiveness-ratio-icer/.
   Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797. doi: 10.1056/NEJMp1405158.
   PubMed Web of Science ®Google Scholar
• American Association for Cancer Research. AACR report on the impact of COVID-19 on cancer research and patient care. Clin Cancer Res. 2022;28(4):609–610.
   Google Scholar
• Muszbek N, Remak E, Evans R, et al. Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma. Future Oncol. 2021;17(9):1055–1068. doi: 10.2217/fon-2020-1004.
   PubMed Web of Science ®Google Scholar
• Rognoni C, Ciani O, Sommariva S, et al. Real-World data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis. Value Health. 2017;20(3):336–344. doi: 10.1016/j.jval.2016.09.2397.
   PubMed Web of Science ®Google Scholar
• Marqueen KE, Kim E, Ang C, et al. Cost-Effectiveness analysis of selective internal radiotherapy with yttrium-90 versus sorafenib in locally advanced hepatocellular carcinoma. J Clin Oncol Oncol Pract. 2021;17(2):e266–e277. doi: 10.1200/OP.20.00443.
   Google Scholar
• Ray CE Jr, Battaglia C, Libby AM, et al. Interventional radiologic treatment of hepatocellular carcinoma-a cost analysis from the payer perspective. J Vasc Interv Radiol. 2012;23(3):306–314. doi: 10.1016/j.jvir.2011.11.016.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9. doi: 10.1016/j.jval.2021.11.1351.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi: 10.1016/s0140-6736(18)30207-1.
   PubMed Web of Science ®Google Scholar
• Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29. doi: 10.1016/s2468-1253(20)30290-9.
   PubMed Web of Science ®Google Scholar
• Rhim H, Lim HK. Radiofrequency ablation of hepatocellular carcinoma: pros and cons. Gut Liver. 2010;4(Suppl 1):S113–S8. doi: 10.5009/gnl.2010.4.S1.S113.
   PubMedGoogle Scholar